​Impact of Adding Genomic Testing (Prolaris) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients with Long Term Follow-up Post-Treatment to Measure the Prediction of Progression/Recurrence in Men Treated in the VA

​This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.

Principal Investigator: Dr. Ralph Torrence
Study Coordinator: Kelley Chadwick-Mansker

This study is now closed to enrollment.

This study was funded by the Foundation through Myriad Genetics